Automated Immunoassay Systems Evaluated for KL‐6 Antigen Quantification
By LabMedica International staff writers Posted on 20 Nov 2019 |
Image: The HISCL-5000 is a fully automated immunoassay analyzer with a throughput of 200 tests per hour. The incubation time for each parameter is 17 minute and allows each laboratory to achieve maximum efficiency and productivity (Photo courtesy of Sysmex Corporation).
Interstitial lung disease (ILD) is a group of diseases characterized by various forms of pulmonary interstitial inflammation and fibrosis, which are usually chronic, progressive, and fatal, causing death 2‐5 years after diagnosis in most patients.
The sputum saccharide chain antigen, Krebs von den Lungen‐6 (KL‐6), is a serum biomarker of lung injury. Since the most important feature of ILD is repeated damage or repair of type II alveolar epithelial cells, KL‐6 is secreted by these cells, and therefore KL‐6 is considered the most accurate biomarker in the diagnosis of ILD.
Immunologists at The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) and their associates collected serum samples from 145 individuals between May 2018 and October 2018. Of 145 subjects, 25 had lung cancer, 56 had ILD, 35 had other respiratory diseases, and 29 were healthy individuals (control group) who underwent regular health checkup. There were 83 (57.24%) men and 62 women with a median age distribution of 56 years (interquartile range: 46-67).
The scientists evaluated the basic performance of KL‐6 assays using the HISCL‐5000 analyzer (Sysmex Corporation, Kobe, Japan), a fully automated immunochemistry analyzer that employs a chemiluminescence enzyme immunoassay (CLEIA) methodology with a two‐step sandwich immunoassay. The results were compared with those from the LUMIPULSE G1200 analyzer (Fujirebio Europe N.V., Zwijnaarde, Belgium). The analytical measurement ranges of HISCL‐5000 and LUMIPULSE G1200 were 10‐6,000 U/mL and 50‐10,000 U/mL, respectively.
The scientists reported that with a cutoff level of 500 U/mL, comparing the two systems, the agreement, sensitivity, specificity, and kappa value were 99.2%, 100%, 98.63%, and 0.984, respectively. Spearman's correlation and intraclass correlation coefficient (ICC) showed that there was a strong correlation between serum KL‐6 levels measured by the two systems. The clinical diagnosis agreement rate in both systems was >80%. The KL‐6 level in the ILD group was significantly higher than that in the non‐ILD groups, and the KL‐6 level (1,558, 726‐2,772.5) in the ILD group detected by HISCL‐5000 was significantly higher than that in the lung cancer group (339, 207‐424), other respiratory disease group (249, 194‐366), and control group (198, 131.5‐297).
The authors concluded that the HISCL‐5000 CLEIA system has a high diagnostic efficiency. The method can be applied to the quantitative detection of serum KL‐6 in patients with respiratory diseases. Compared with those in other respiratory diseases, the serum KL‐6 level in patients with ILD is significantly increased, suggesting that clinicians can use KL‐6 in the auxiliary diagnosis of ILD. The study was published on November 6, 2019 in the Journal of Clinical Laboratory Analysis.
Related Links:
The First Affiliated Hospital of Guangzhou Medical University
Sysmex Corporation
Fujirebio Europe N.V.
The sputum saccharide chain antigen, Krebs von den Lungen‐6 (KL‐6), is a serum biomarker of lung injury. Since the most important feature of ILD is repeated damage or repair of type II alveolar epithelial cells, KL‐6 is secreted by these cells, and therefore KL‐6 is considered the most accurate biomarker in the diagnosis of ILD.
Immunologists at The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) and their associates collected serum samples from 145 individuals between May 2018 and October 2018. Of 145 subjects, 25 had lung cancer, 56 had ILD, 35 had other respiratory diseases, and 29 were healthy individuals (control group) who underwent regular health checkup. There were 83 (57.24%) men and 62 women with a median age distribution of 56 years (interquartile range: 46-67).
The scientists evaluated the basic performance of KL‐6 assays using the HISCL‐5000 analyzer (Sysmex Corporation, Kobe, Japan), a fully automated immunochemistry analyzer that employs a chemiluminescence enzyme immunoassay (CLEIA) methodology with a two‐step sandwich immunoassay. The results were compared with those from the LUMIPULSE G1200 analyzer (Fujirebio Europe N.V., Zwijnaarde, Belgium). The analytical measurement ranges of HISCL‐5000 and LUMIPULSE G1200 were 10‐6,000 U/mL and 50‐10,000 U/mL, respectively.
The scientists reported that with a cutoff level of 500 U/mL, comparing the two systems, the agreement, sensitivity, specificity, and kappa value were 99.2%, 100%, 98.63%, and 0.984, respectively. Spearman's correlation and intraclass correlation coefficient (ICC) showed that there was a strong correlation between serum KL‐6 levels measured by the two systems. The clinical diagnosis agreement rate in both systems was >80%. The KL‐6 level in the ILD group was significantly higher than that in the non‐ILD groups, and the KL‐6 level (1,558, 726‐2,772.5) in the ILD group detected by HISCL‐5000 was significantly higher than that in the lung cancer group (339, 207‐424), other respiratory disease group (249, 194‐366), and control group (198, 131.5‐297).
The authors concluded that the HISCL‐5000 CLEIA system has a high diagnostic efficiency. The method can be applied to the quantitative detection of serum KL‐6 in patients with respiratory diseases. Compared with those in other respiratory diseases, the serum KL‐6 level in patients with ILD is significantly increased, suggesting that clinicians can use KL‐6 in the auxiliary diagnosis of ILD. The study was published on November 6, 2019 in the Journal of Clinical Laboratory Analysis.
Related Links:
The First Affiliated Hospital of Guangzhou Medical University
Sysmex Corporation
Fujirebio Europe N.V.
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes